(Q41006179)

25 September 2017

1 reference

title

Vinorelbine: an overview (English)

1 reference

25 September 2017

Johnson SA

1

1 reference

25 September 2017

Harper P

series ordinal

2

1 reference

25 September 2017

Hortobagyi GN

series ordinal

3

1 reference

25 September 2017

Pouillart P

series ordinal

4

1 reference

25 September 2017

1 March 1996

1 reference

25 September 2017

Cancer Treatment Reviews

1 reference

25 September 2017

22

1 reference

25 September 2017

127-142

1 reference

25 September 2017

2

1 reference

Microtubule Formation in vitro in Solutions Containing Low Calcium Concentrations

25 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Experimental antitumor activity of 5'-nor-anhydrovinblastine navelbine

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Effective combination therapy of metastatic murine solid tumors with edatrexate and the vinca alkaloids, vinblastine, navelbine and vindesine

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Evaluation of antitumor activity of navelbine (vinorelbine ditartrate) against human breast carcinoma xenografts based on its pharmacokinetics in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Combination effect of navelbine (vinorelbine ditartrate) with cisplatin against murine P388 leukemia and human lung carcinoma xenografts in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine)

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Pharmacokinetics of vinorelbine in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Pharmacokinetics of navelbine after oral administration in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Phase I pharmacologic study of a new Vinca alkaloid: navelbine

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Pulmonary distribution of vinorelbine in patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Japan Vinorelbine Lung Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Efficacy and toxicity of vinorelbine-carboplatin combination in the treatment of advanced adenocarcinoma or large-cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Vinorelbine as first-line chemotherapy for metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

A phase II, multicentre, UK study of vinorelbine in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

A phase II trial of vinorelbine and thiotepa in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Vinorelbine in pre-treated advanced head & neck squamous cell carcinoma. A phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

Phase II study of navelbine in advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2896%2990032-8

7 January 2021

10.1016/S0305-7372(96)90032-8

Identifiers

DOI

1 reference

25 September 2017

1 reference